Oncology
Refine search
Biotechnology
Oxford, UK-based Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX 011, a first in class, mutation agnostic antibody with potential to disrupt the $2 billion essential thrombocythemia (ET) market. 16 April 2026
Biotechnology
US biotech Terremoto Biosciences, a firm developing highly-targeted small molecule medicines, has announced the closing of a $108 million Series C financing round. 16 April 2026
Biotechnology
UK-based STORM Therapeutics, a biotech targeting RNA modifications to reprogram cells and develop novel cancer therapies, has announced a successful $56 million Series C financing. 16 April 2026
Pharmaceutical
US-based Sonire Therapeutics has secured $18 million in Series A financing to advance clinical development of its non-invasive cancer therapy, with a focus on pancreatic cancer. The round was led by Santé Ventures, with participation from Fast Track Initiative, Nomura SPARX Investment and SBI Investment. 16 April 2026
Pharmaceutical
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines priced 10.56 million shares to raise $1.5 billion and $500 million in convertible senior notes due 2033. 16 April 2026
Biotechnology
Privately-held Swiss drug firm Ewopharma has reported that sugemalimab, licensed from Chinese partner CStone Pharmaceuticals, has received I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. 16 April 2026
Pharmaceutical
Johnson & Johnson has announced its financial results for the first quarter of 2026. 15 April 2026
Biotechnology
USA-based Galera Therapeutics and Obsidian Therapeutics, a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte (TIL) cell therapies, announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. 15 April 2026
Biotechnology
San Diego, USA-based biotech Neomorph has announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others. 15 April 2026
Biotechnology
Texan pre-clinical stage biotech CrossBridge Bio, a developer of dual-payload antibody-drug conjugates (ADCs), has announced a definitive agreement to be acquired by US pharma major Eli Lilly. 14 April 2026
Biotechnology
Eli Lilly has announced positive top-line results from the Phase III BRUIN CLL-322 trial. 14 April 2026
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Biotechnology
Chinese clinical-stage biotech OriCell Therapeutics announced the cumulative closing of a pre-initial public offering (IPO) financing round in excess of $110 million. 13 April 2026
Biotechnology
US biotech Replimune has suffered a fresh blow after the US Food and Drug Administration rejected its lead cancer therapy RP1 (vusolimogene oderparepvec), sending shares sharply lower and casting doubt over the program’s future. 13 April 2026
Biotechnology
Important news last week kicked off with Neurocrine Biosciences announcing a proposed $2.9 billion takeover bid for Solena Therapeutics. Then Gilead Sciences revealed an up to $5 billion takeover for German antibody-drug conjugate (ADCs) developer Tubulis. Also of note, Sanofi released mixed Phase II results for its asthma and dermatology candidate lunsekimig. The US Food and Drug Administration (FDA) announced plans for greater control of direct-to-consumer Rx medicines advertising. 12 April 2026
Biotechnology
German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment. 11 April 2026
Biotechnology
Japanese drugmaker Daiichi Sankyo is deepening its push into AI-driven oncology, partnering with USA-based Imagene AI to advance biomarker discovery and response prediction across its cancer pipeline. 10 April 2026
Pharmaceutical
Tempus AI , a technology company leading the adoption of AI to advance precision medicine, has announced an expanded, multi-year collaboration with Gilead Sciences aimed at building and advancing Gilead’s oncology pipeline. 10 April 2026
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience saw its shares jump 28.7% to 0.20 kronor this morning, after it provided a brief update regarding its mitazalimab. 10 April 2026
Biotechnology
US clinical-stage biotech C4 Therapeutics (C4T) announced that it has entered into a new collaboration agreement with Roche to advance research in the emerging degrader-antibody conjugate (DAC) modality. 10 April 2026
Pharmaceutical
US pharma major AbbVie has filed a lawsuit seeking to narrow the definition of a “340B patient,” opening a new legal front in a long-running dispute over the US drug discount program. 9 April 2026
Pharmaceutical
US biotech Sidewinder Therapeutics has secured $137 million in an oversubscribed series B financing to advance its bispecific antibody-drug conjugate (ADC) pipeline for cancer. 9 April 2026
Biotechnology
Late last year, Julie Dehaene-Puype stepped into the role of Regional President at Kyowa Kirin International (KKI), a specialty pharma developing innovative treatments for rare and genetic diseases, including bone and mineral disorders, rare blood cancers and other inherited genetic conditions. 8 April 2026
Pharmaceutical
Chinese nuclear medicine company New Radiomedicine Technology (NRT) has raised more than 1 billion yuan ($145.3 million) in a series E round, underscoring rising investor interest in radiopharmaceuticals as oncology assets edge closer to clinical inflection points. 8 April 2026
Biotechnology
German drug developer Evotec reported fourth-quarter 2025 revenue of $293 million, up 14%, and adjusted EBITDA of $67 million, up 103%, driven largely by a license payment linked to the sale of its Toulouse biologics site to Sandoz. 8 April 2026
Biotechnology
US biotech major Gilead Sciences is to acquire Tubulis, a privately-held German biotech developing next-generation antibody-drug conjugates (ADCs). 7 April 2026
Pharmaceutical
Norway based immune-oncology medicines developer Lytix Biopharma today announced the appointment of Renée Christine Amundsen as chief operating officer (COO), effective immediately. 7 April 2026
Biotechnology
US biotech Stipple Bio has emerged from stealth with a $100 million series A, aiming to refine antibody-drug conjugates by targeting cancer cells at the epitope level rather than relying on payload or linker innovation. 7 April 2026
Biotechnology
Syneron Bio, a China based leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31. The news comes less than four months after Syneron closed its Series A and A+ rounds at close to $100 million in total. 7 April 2026
Pharmaceutical
Important research news last week included US pharma giant Merck & Co moving its Winrevair into Phase III for pulmonary arterial hypertension. On the M&A front, Biogen announced a $5.6 billion takeover for Apellis and its two main products – Empaveli and Syfovre. Eli Lilly’s oral obesity drug orforglipron has been granted US Food and Drug Administration (FDA) in a record time, under the trade name Foundayo. Also of note, Sino-American biotech Adagene struck a deal with the USA’s Incyte to evaluate muzastotug in colorectal cancer. 5 April 2026
Generics
India has moved ahead in developing indigenous capacity for cell and gene therapies, with regulatory bodies issuing national guidelines to ensure safe and ethical deployment of CRISPR-based technologies. 3 April 2026
Pharmaceutical
Independent French pharma major Servier announced that the UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Voranigo (vorasidenib). 3 April 2026
Biotechnology
French biotech company Transgene , which develops virus-based immunotherapies for the treatment of cancer, and NEC Bio, a wholly owned subsidiary of NEC Corporation, a leader in IT, network and AI technologies, have signed a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. s 3 April 2026
Biotechnology
Sino-American antibody company Adagene announced three separate updates on its activities at once on Thursday. 2 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze